EDAP TMS SA (EDAP), a global leader in robotic energy-based therapies, has signed a letter of intent with the European Investment Bank - EIB for a EUR 36 million credit facility.
The funding will support the expansion of the company's Focal One® Robotic HIFU platform in focal therapy, a rapidly growing treatment option for early-stage prostate cancer, and accelerate research into additional clinical applications. The facility is expected to close by the end of 2025, pending completion of final legal documentation.
EDAP's CEO, Ryan Rhodes, highlighted that the agreement provides a significant source of low-interest funding, strengthening the company's balance sheet and enabling flexible access to capital. He acknowledged EIB's longstanding role in advancing innovative medical technologies and expressed confidence that the financing will broaden physician and patient access to Focal One Robotic HIFU.
Tuesday, EDAP closed at $1.52, up 10.95%, and is trading after hours at $1.53, up 0.66%, on the NasdaqGM.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.